… Univariable and multivariable logistic regression analysis was performed to determine factors
associated with hospital admission and adverse reactions. Statistical significance was set …

… This study investigated the association between nirmatrelvir plus ritonavir (NMV-r) and
the outcomes of non-hospitalized obese patients with coronavirus disease 2019 (COVID-19). …

… covers by law all hospitalizations in general hospitals outside the MHS network, as well as
visits to urgent care center and ER in hospitals (including cases where a co-pay is required). …

… We found that patients in the nirmatrelvir/ritonavir groups had longer hospital stays (P=0.002)
and higher hospital expenses (P<0.001), compared with patients in the azvudine groups ( …

… of the clinical effectiveness and safety of nirmatrelvir/ritonavir and azvudine in hospitalized
COVID-19 patients at the Tongji Hospital, as the largest hospital in the central region of China …

… The combination nirmatrelvir/ritonavir (NMV/r) received … Due to the inclusion of ritonavir in
the regimen, several drug … tides of the pandemic by reducing hospital admissions and mortality. …

… symptoms for >5 days before admission. This implies that many patients missed … hospital
admission. However, NMVr was only supplied to hospitalized patients in participating hospitals, …

… The authors suggested that molnupiravir might reduce hospital admission rates or death
rates at 30 days compared to no treatment [40]. In addition, a large US cohort study of 229,286 …

… nirmatrelvir plus ritonavir. Lastly, a significant reduction in the risk of death associated with
nirmatrelvir plus ritonavir … Molnupiravir and risk of hospital admission or death in adults with …

… The aim of this study was to investigate the clinical efficacy of a combination of nirmatrelvir
and ritonavir (NMV-r) for treating COVID-19 in patients with diabetes mellitus (DM). This …